Introduction: germline predisposition in myeloid neoplasms {#sec1}
==========================================================

Nearly a decade ago the first classical inherited bone marrow failure (BMF) syndrome predisposing to myeloid neoplasms (MN) had been reported by the paediatrician Guido Fanconi, and later named Fanconi Anemia (FA) \[[@bib1]\]. Since then, a number of additional inherited BMF syndromes with risk for the development of myelodysplastic syndrome (MDS) and leukemia have been discovered, including severe congenital neutropenia (SCN), Shwachman Diamond syndrome (SDS), telomere biology disorders/dyskeratosis congenita, Down syndrome, RASopathies, and DNA repair disorders \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]\]. These syndromes are usually straightforward to diagnose because of preexisting syndromic features and haematological symptoms arising from abnormalities of hematopoietic stem and progenitor cells. The characteristics of recurrently occurring genetic syndromes are outlined in [Table 1](#tbl1){ref-type="table"} . Although BMF manifests early in live, MDS and leukemia develop as a secondary disease after a latency of years to decades from diagnosis of the underlying condition \[[@bib5],[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16]\]. Clonal evolution is usually associated with a number of recurrent somatic mutations, for example [RUNX1]{.ul} in FA, [CSF3R]{.ul} and [RUNX1]{.ul} in SCN, [TP53]{.ul} and [EIF6]{.ul} in SDS, [GATA1]{.ul} short and cohesin genes in Down syndrome \[[@bib5],[@bib7],[@bib10],[@bib12],[@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23]\]. Additional mutations can involve typical leukemia drivers including RAS pathway genes, [SETBP1]{.ul}, [ASXL1]{.ul}, [EZH2]{.ul}, and others. Recurrent karyotype abnormalities are also found, particularly loss of chromosome 7 (monosomy 7 (−7), del(7q), der(1; 7), isochromosome 7q), trisomy 8 (+8), or trisomy 21 (+21). While most of the somatic mutations are known leukemia drivers ([RUNX1]{.ul}, RAS pathway, [TP53]{.ul}), others might represent benign adaptive responses ([EIF6]{.ul}, [CSF3R]{.ul}). In addition, revertant somatic events including back mutations or uniparental disomy have been reported in FA and [TERT/TERC]{.ul} mutated telomere biology disorders \[[@bib24], [@bib25], [@bib26], [@bib27]\].Table 1Germline syndromes predisposing to myeloid neoplasms.Table 1Disease/GeneRisk for MNAge of MN onset, years \*Population at High Risk for MNReported somatic mutationsReported karyotypesCongenital anomaliesImmune deficiencyGermline predisposition to myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)GATA2High0.4--78 (∼20)Children -- AdultsSETBP1, ASXL1, RUNX1, PTPN11, NRAS, KRAS, CBL, EZH2, ETV6, STAG2, JAK3, IKZF1, CRLF2, IDH2, TP53−7, der(1; 7), +8, +21++++SAMD9, SAMD9LModeratePediatric age, not yet definedChildrenSETBP1, ASXL1, RUNX1, PTPN11, KRAS, CBL, EZH2, ETV6, BRAF, RAD21−7, del(7q), del12p13.2, UPD7q++--Somatic revertant mosaicism (cis SAMD9/9L, UPD7q)RUNX1High6-77 (∼33)Children -- AdultsRUNX1 (trans mutation or duplication via LOH), ASXL1, BCOR, DNMT3A, PHF6, WT1, GATA2, FLI1, JMJD5, KDM6B, CDC25C+21, +8, −7----CEBPAHigh2-50 (∼25)Children -- AdultsCEBPA (trans mutation at 3′ end), GATA2, WT1, EZH2, TET2, SMC3, NRAS, DDX41, CSF3R----ETV6Moderate (mostly ALL)8--82AdultsBCOR, RUNX1, NRAS----DDX41Moderate6-93 (∼55)AdultsDDX41 (trans p.Arg525His mutation, p.Ala255Asp, p.Glu247Lys, p.Pro321Lys)del(20q), del(7q), −7, +8----ANKRD26Low\>30Adults----TET2 (1 family with p.K1363fs mutation)Not known53-61 (60)AdultsTET2 (p.His863fs), BRAF, ZRSR2, SRSF2, JAK2, GATA2------Classical inherited bone marrow failure syndromesFanconi Anemia22 FA genesHigh0.1--49 (13)ChildrenSomatic revertant mosaicisms (back mutations),del(7q), dup(1q), dup(3q), complex++--RUNX1Severe Congenital Neutropenia\
ELANE, G6PC3, HAX1, JAGN1, GFI1, VPS45A, TCRG1High2-49 (12)Children -- AdultsCSF3R, RUNX1, RAS genes−7, del(7q), +21+--Shwachman Diamond Syndrome\
SBDS, ELF1, SRP54, DNAJC21VariableMDS: 5--42 (8)Children -- AdultsTP53 (\>50% of cases with SBDS germline mutation), EIF6, PRPF8, CSNK1A1, U2AF1, IDH1, RUNX1, SETBP1, NRAS, KRAS, BRAF, DNMT3A, TET2, ASXL1isochromosome 7q,\
−7, del(20q)++(+)Telomere Biology Disorders\
[DC]{.ul}: TERC, TERT, DKC1, RTEL1, TINF2, ACD, CTC1, NHP2, NOP10, NPM1, PARN, WRAP53\
Pulmonary fibrosis: POT1, ZCCHC8, NAF1\
CLL/Melanoma: POT1Moderate (mostly adults)19-61 (35)AdultsSomatic revertant mosaicism (UPD of TERT/TERC allele, or activating TERT promoter mutations -- very rare);++Leukemia mutations uncommonDown syndrome and rasopathiesTrisomy 21Moderate1-4 (1.5)ChildrenGATA1 short, cohesin (RAD21, STAG2, NIPBL, SMC1A, SMC3), CTCF, EZH2, KANSL1, BCOR, WT1, DCAF7 TP53, NRAS, KRAS, PTPN11, JAK2, JAK3, SH2B3MLL gene rearrangements, complex++(+)Rasopathies\
NF1, CBL, PTPN11, NRAS, KRASModerateCBL: 0.1--3.6 (1.1)ChildrenDuplicaton of mutant allele (via UPD), additional Ras pathway mutations−7++--DNA repair syndromesERCC6L2High14-65 (38)AdultsTP53, IDH1−7, +20, −18, del(5q)+--Xeroderma pigmentosum C (XP-C)Low7-29 (25)AdultsTP53, CSF3R, TET2, RAD21−7, del(5q), complex+--OtherTP53, CMMRD, Werner-/Bloom syndrome, NBS, AT, Ligase IV deficiencyMN are rareAll agesChildren -- AdultsChromothripsis−7, complex++[^1][^2][^3]

The identification of germline mutations in RUNX1 (1999) and CEBPA (2004) initiated a new era for the discovery of monogenic disorders predisposing to MN \[[@bib28],[@bib29]\]. For the most part these "new" syndromes result from heterozygous mutations in haematopoietic transcription factors or regulators ([GATA2]{.ul}, [RUNX1]{.ul}, [CEBPA]{.ul}, [ETV6]{.ul}, [DDX41]{.ul}, [SAMD9]{.ul}, [SAMD9L]{.ul}, and [TET2]{.ul}, [Table 1](#tbl1){ref-type="table"}) \[[@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37]\]. These syndromes often pose unique diagnostic challenges. First, the full spectrum of clinical and genetic manifestations is not yet fully defined, forcing us to adopt the "expect the unexpected "approach for the workup of such cases. Second, unlike the classical inherited BMF syndromes which are often diagnosed based on medical history, these new syndromes can often manifest with MN without preceding clinical problems. And finally, many patients have negative family history (even in families with multiple mutated individuals) which can be attributed to incomplete penetrance/variable expressivity and a considerable rate of *de novo* germline mutations. Despite these challenges, there are genetic and phenotypic patterns that can serve as diagnostic red flags. These can include certain types of mutations that are identified on a somatic sequencing panel, for example mutations with allelic frequency nearly 50% in a patient without significant blast increase, [DDX41]{.ul} somatic hotspot mutation that co-occurs with germline [DDX41]{.ul} mutations, bi-allelic [CEBPA]{.ul} mutation with one mutation positioned at 3′-end, and finally the specific localization of mutations like missense [GATA2]{.ul} mutations in zinc finger 2. In addition, certain clinical signs can be syndrome-specific, i.e. lymphedema, hydrocele, and congenital deafness in GATA2, ataxia in SAMD9L, adrenal hypoplasia in SAMD9, or preceding thrombocytopenia in individuals with RUNX1/ETV6/ANKRD26 mutations.

GATA2 and SAMD9/SAMD9L syndromes are the most frequent predisposing conditions in children and adolescents with primary MDS and are associated with the development of monosomy 7: collectively they account for at least 50% of pediatric MDS with monosomy 7 \[[@bib30],[@bib37], [@bib38], [@bib39]\]. The following text will discuss in detail the clinical and genetic spectrum of GATA2 and SAMD9/SAMD9L syndromes.

GATA2 deficiency {#sec2}
================

GATA2 is a key transcription factor critical for ontogenesis of haematopoietic system, including haematopoietic stem cell (HSC) activity and self-renewal, myeloid and myelo-erythroid progenitor cell differentiation, and erythroid precursor cell maintenance \[[@bib40], [@bib41], [@bib42], [@bib43], [@bib44]\]. In the past decade, heterozygous germline [GATA2]{.ul} mutations have been identified in a number of cohorts with cellular deficiencies (immunodeficiency syndromes initially referred to as MonoMAC syndrome, DCML deficiency, Emberger syndrome, chronic neutropenia) \[[@bib45], [@bib46], [@bib47], [@bib48]\], and in patients with familial MDS and acute myeloid leukemia (AML), as well as pediatric MDS \[[@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53]\]. To date, approximately 150 unique [GATA2]{.ul} germline mutations have been identified in roughly 550 patients ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Clinical characteristics of GATA2 deficiency and SAMD9/9L syndromes.Key information referring to phenotypes, prevalence and genetics are summarized in the outside coloured boxes; clinical manifestations are depicted in the middle. Abbreviations: MonoMAC, Monocytopenia and *Mycobacterium avium* complex infection syndrome; DCML, Dendritic cell, Monocytes, B/NK Lymphocytes deficiency; MDS, Myelodysplastic Syndrome; MDS-EB, MDS with Excess of Blasts; AML, Acute Myeloid Leukemia; −7, monosomy 7; LOF, loss of function; ADHD, Attention Deficit Hyperactivity Disorder; PAP, Pulmonary Alveaolar Proteinosis; NTM, Nontuberculous mycobacteria; VUR, Vesicoureteral Reflux; IUGR, Intrauterine Growth Restriction; MIRAGE, Myelodysplasia, Infection, growth Restriction, Adrenal hypoplasia, Genital phenotypes, and Enteropathy; CANDLE, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperaturę; ICUS, idiopathic cytopenia of unknown significance (denotes children with unclear cytopenia and suspected bone marrow failure); GOF, gain of function.Fig. 1

Penetrance and prevalence {#sec2.1}
-------------------------

GATA2 deficiency follows an autosomal dominant inheritance pattern with the majority (up to 80%) of cases arising *de novo* \[[@bib49],[@bib52], [@bib53], [@bib54], [@bib55]\]. Although the lifetime penetrance for the development of MN is very high, incomplete penetrance is possible, as suggested by the presence of several asymptomatic mutation carriers of various ages within affected families \[[@bib50],[@bib52],[@bib53],[@bib56], [@bib57], [@bib58]\]. Recently, distinct patterns of [GATA2]{.ul} promoter methylation leading to disbalance in allelic expression have been identified in 2 patients and proposed as a mechanism for reduced clinical expressivity \[[@bib59],[@bib60]\].

Summarizing published cohort studies and smaller case series, approximately 75% of [GATA2]{.ul} mutation carriers develop MN at an estimated median age of 20 years ([Table 1](#tbl1){ref-type="table"}). The spectrum of MN includes primary pediatric MDS, AML, chronic myelomonocytic leukemia (CMML) and myeloproliferative neoplasms \[[@bib47],[@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55],[@bib61]\]. In children and adolescents with primary MDS, GATA2 deficiency is a predominant germline predisposition accounting for 7% of all MDS cases, 15% of patients with advanced MDS, and 37% of patients with MDS and −7 karyotype \[[@bib52],[@bib62]\]. Among children, the prevalence of GATA2 deficiency increases with age, and 2/3 of adolescents with MDS and monosomy 7 carry germline GATA2 mutations. In adult MDS, GATA2 deficiency is rare and present in less than 0.5% of individuals \[[@bib52]\], however the true prevalence in various age groups has yet to be defined.

Clinical presentation {#sec2.2}
---------------------

The initial haematological presentation in patients with GATA2 deficiency can be very variable, ranging from cytopenias and hypocellular BMF-like picture, severe immunodeficiency to myeloid neoplasms. Many patients often lack family history of MDS and exhibit mild initial symptoms with preceding cellular deficiencies \[[@bib49],[@bib52],[@bib62]\]. However, MDS can also manifest as a stand-alone diagnosis without preceding cytopenia. [GATA2]{.ul} deficient patients often suffer from preexisting monocytopenia, B-cell and NK-cell lymphopenia, reduction/lack of CD56^bright^ NK cells and dendritic cells, inverted ratio of CD4:CD8 cells, and chronic neutropenia \[[@bib48],[@bib53],[@bib58],[@bib61], [@bib62], [@bib63], [@bib64], [@bib65]\]. Immune deficiency is typically recorded as a consequence of profound cytopenias and loss of functional stem cells \[[@bib66]\]. When compared to other marrow failure conditions in children, reduced progenitor and mature B-cells are the most constant feature of GATA2 deficiency \[[@bib62]\]. Notably, monocytosis has been observed at diagnosis in GATA2 patients with MDS and is likely attributed to disease progression \[[@bib52],[@bib53]\], although transient monocytosis in infancy has been also observed (unpublished own observations). The immunological phenotypes are heterogeneous. Many patients can initially present with HPV-related infections (warts, generalized verrucosis, cervical intraepithelial neoplasia), disseminated nontuberculous mycobacterial, as well as systemic bacterial and fungal infections \[[@bib50],[@bib53],[@bib67]\]. Recurrent respiratory tract infections can result in a development of pulmonary alveolar proteinosis (PAP) or interstitial lung disease \[[@bib50],[@bib53]\]. Moreover, compromised function of the immune system may contribute to malignant transformation of HPV- or EBV-related neoplasia and increased occurrence of other solid tumors \[[@bib47],[@bib50],[@bib53],[@bib68]\]. Furthermore, [GATA2]{.ul} mutated patients have been repeatedly shown to suffer from autoimmune dysregulation such as autoimmune cytopenia, arthritis, panniculitis, erythema nodosum, psoriasis, lupus-like syndrome and autoimmune hepatitis \[[@bib53],[@bib56],[@bib63],[@bib69], [@bib70], [@bib71]\].

[GATA2]{.ul}-MDS patients demonstrate heterogeneous morphological features involving hypocellular marrow with cytopenias, or normal to hypercellular marrow in case of advanced MDS. Frequently recognized dysplasia is seen in megakaryocyte lineage, but other lineages are also affected \[[@bib50],[@bib63]\].

Apart from haematological and immunological symptoms, at least 50% of GATA2-deficient patients present with constitutional abnormalities affecting different organ systems ([Fig. 1](#fig1){ref-type="fig"}). In addition to lymphedema, hydrocele and congenital deafness, abnormalities of pulmonary, cardiovascular, urogenital and neurological systems have been repeatedly observed \[[@bib48],[@bib50],[@bib52],[@bib53],[@bib56],[@bib62],[@bib63]\]. This includes i.e. PAP, thrombosis, pulmonary embolism, vesicoureteral reflux, hypospadias, hydrocele, developmental delay, or behavioral disorders/ADHD. The presence of both immune deficiency and typical constitutional features, especially in context of MDS should trigger genetic workup for [GATA2]{.ul} mutations.

GATA2 germline mutations {#sec2.3}
------------------------

*De novo* or inherited heterozygous loss of function mutations have been identified as the genetic basis of GATA2 deficiency. These mutations are thought to lead to loss of function of GATA2 protein (through loss of one allele or malfunctioning protein) specifically abolishing the DNA-binding function of the C-terminal zinc finger (ZF2) \[[@bib47],[@bib49],[@bib72], [@bib73], [@bib74], [@bib75], [@bib76], [@bib77], [@bib78], [@bib79]\]. Overall, 3 main mutation categories can be distinguished i.e. null (frameshift, nonsense, splice site and whole gene deletions) located prior or within ZF2 and accounting for around two thirds of all reported variants, missense substitutions clustered within ZF2 representing one third of [GATA2]{.ul} mutations and intronic alterations affecting +9.5 kb enhancer element (EBOX-GATA-ETS) detected in ∼5--10% of cases ([Fig. 1](#fig1){ref-type="fig"}). Additionally, rare changes including in-frame deletions/insertions and missense mutations downstream of ZF2 were found \[[@bib80]\]. Most recently, we identified 5 heterozygous synonymous [GATA2]{.ul} mutations (p.Thr117Thr, p.Leu217Leu, p.Gly327Gly, p.Ala341Ala, p.Pro472Pro) in 9 patients with GATA2 deficiency that led to selective loss of mutated copy of [GATA2]{.ul} mRNA \[[@bib59],[@bib81]\]. The hotspot p.Thr117Thr mutation has been also described by others \[[@bib77],[@bib82]\] and mechanistically was found to introduce a new splice donor resulting in premature translation termination associated with nonsense-mediated decay.

Experimental studies found impaired ability of mutant GATA2 protein to bind DNA and activate transcription of target genes. This was shown for several mutations (p.Arg330X, p.Ala345delinsALLVAALLAA, p.Thr354Met, p.Thr355del, p.Thr358Asn, p.Arg361Leu, p.Cys373Arg, p.Arg396Gln, p.Arg396Leu, p.Arg398Trp) \[[@bib47],[@bib49],[@bib73], [@bib74], [@bib75], [@bib76],[@bib79]\]. Moreover, some of the mutations were shown to affect proliferation, differentiation and apoptosis in haematopoietic cells \[[@bib49],[@bib74]\]. Variable expressivity of [GATA2]{.ul} ZF2 germline mutations is common. The most recurrent mutations p.Thr354Met, p.Arg396Gln and p.Arg398Trp all predispose to myeloid malignancies, however p.Thr354Met was shown to be associated with MDS as initial presentation, while p.Arg396Gln and p.Arg398Trp mutations were suggested to correlate with a phenotype of immunodeficiency manifesting prior malignant transformation \[[@bib75]\]. Although, reduced DNA-binding/transactivation ability has been shown to be causal of GATA2 haploinsufficiency, this does not explain the genotype/phenotype correlation for individual ZF2 mutations. One possible explanation could be the altered interaction between [GATA2]{.ul} and other proteins, as shown for [GATA2]{.ul} p.T354 M and p.C373R mutations that compared to wild type GATA2 protein bind more strongly to the hematopoietic differentiation factor PU.1 \[[@bib75]\]. Hence, detailed mechanistic studies are paramount to understand these phenotypic differences and functional consequences of germline [GATA2]{.ul} mutations. Genotype-phenotype correlative analyses have thus far been unsuccessful. In a recent study encompassing 79 French patients with GATA2 deficiency, patients harboring missense mutations (14 out of 38) were more likely to develop leukemia than patients with frameshift mutations (2 out of 28; p = 0.007) \[[@bib53]\]. However, an analysis conducted by our group in a large cohort of pediatric MDS (N = 137) did not confirm this association (own unpublished observations).

Somatic [GATA2]{.ul} mutations compared to germline mutations show different localization within the protein and are associated with other haematological phenotypes. Of the roughly 50 reported somatic mutations, the majority are found within the boundaries of N-terminal zinc finger (ZF1), but some mutations also occur in ZF2 \[[@bib83]\]. These mutations are generally rare and were identified in pediatric and adult AML (predominantly accompanied by biallelic [CEBPA]{.ul} mutations), chronic myeloid leukemia in blast crisis, as well as acute eosinophilic leukemia \[[@bib84], [@bib85], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90], [@bib91], [@bib92], [@bib93]\]. In contrast to germline variants, acquired [GATA2]{.ul} mutations were characterized as either LOF (p.Pro304His, p.Leu321Val, p.Leu321Pro, p.Arg330Gln, p.Arg362Gln, p.Ala341_Gly346del) or gain-of-function (GOF; p.Gly320Asp, p.Leu359Val). It is interesting to note that certain somatic [GATA2]{.ul} ZF2 mutations in adults with MN can "phenocopy" symptoms of GATA2 germline disorder, i.e. immunodeficiency (monocytopenia, low B-/NK-cells, recurrent infections) accompanied by lymphedema or PAP \[[@bib94],[@bib95]\].

Acquired cytogenetic and genetic aberrations {#sec2.4}
--------------------------------------------

The most common karyotype abnormalities are monosomy 7 or der(1; 7) that can occur in up to 80% of GATA2-related MDS patients, with average estimate across all published studies of ∼41% ([Fig. 2](#fig2){ref-type="fig"} ) \[[@bib39]\]. Trisomy 8 is the second most common aberration identified in up to 40% of patients in single cohorts, and an average of 15% across published studies. Additional common abnormality trisomy 21, while complex karyotypes are generally not encountered. GATA2-related MDS is also associated with acquired MDS/leukemia driver mutations ([Table 1](#tbl1){ref-type="table"}). Recurrent mutations were identified in genes [ASXL1]{.ul}, [SETBP1]{.ul}, [RUNX1]{.ul}, [STAG2]{.ul}, [CBL]{.ul}, [EZH2]{.ul}, [NRAS, KRAS]{.ul}, [JAK3]{.ul}, [PTPN11]{.ul} *.* \[[@bib51],[@bib54],[@bib58],[@bib96], [@bib97], [@bib98], [@bib99], [@bib100]\] Furthermore, single GATA2-MDS cases were reported with somatic mutations in [IKZF1]{.ul}, [CRLF2]{.ul}, [HECW2]{.ul}, [GATA1]{.ul}, [GATA2]{.ul}, [ATRX]{.ul}, [BRCA2]{.ul}, [GPRC5A]{.ul}, [IDH2]{.ul}, [TP53]{.ul}, [WT1]{.ul} \[[@bib97],[@bib99],[@bib101]\].Fig. 2**Monosomy 7 driven mechanisms of clonal evolution in MDS predisposition syndromes.**Malignant transformation of GATA2 deficiency (outside left box), SAMD9/9L disorders (middle boxes) and other predisposing syndromes (outside right box) is associated with loss of whole chromosome 7 or its long (7q) arm followed by acquisition of somatic mutations in leukemia-related genes. Loss of chromosome 7 is non-random in SAMD9/9L syndromes and leads to loss of germline SAMD9/9L mutation. Revertant clonal hematopoiesis in SAMD9/9L syndromes arise from UPD7q or acquired truncating SAMD9/9L mutation (middle right box). MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; UPD, uniparental disomy.Fig. 2

Therapeutic considerations {#sec2.5}
--------------------------

There are no consensus guidelines on management of GATA2 deficiency and the surveillance strategies are individually tailored. Most patients are being followed by haematologists, immunologists or transplant physicians and general recommendations include periodic assessment of complete blood counts and immune status, yearly bone marrow evaluation with cytogenetics and somatic mutational testing, as well as screening for HPV-related cancers and pulmonary symptoms. Haematopoietic stem cell transplantation (HSCT) is the only curative treatment with reported outcomes ranging from 54% (4 year overall survival (OS)) in adults transplanted for MDS/AML or immunodeficiency \[[@bib50]\], to 66% (5 year OS) in children transplanted for MDS with monosomy 7 \[[@bib52]\], or 62% (5 year OS) in a French [GATA2]{.ul} cohort \[[@bib53]\], and 86% (2 year disease-free survival) in young adults with MDS \[[@bib68]\]. Because monosomy 7 is associated with a high risk of progression to more advanced MDS, patients with monosomy 7 should receive HSCT as soon as possible \[[@bib102]\]. While myeloablative conditioning is preferred in MDS with monosomy 7 (independent of blasts) as well as advanced MDS/AML, reduced intensity conditioning might be preferred option in patients with hypocellular MDS without high risk somatic alterations, as well as patients with immunodeficiency alone. HSCT was shown to reverse HPV-related lesions as well respiratory problems (PAP) \[[@bib68],[@bib103], [@bib104], [@bib105]\]. Patients with stable disease course, without relevant infections, bone marrow dysplasia and transfusion-dependency might qualify for a watch & wait strategy \[[@bib106],[@bib107]\]. However, it can be assumed that most GATA2-deficient patients show progressive disease and even with careful watching the best opportunity for low risk HSCT might be missed. Currently, transplant indications include progressing immunodeficiency with recurrent infections, respiratory complications (PAP), transfusion-dependency, and MDS \[[@bib50],[@bib52],[@bib104],[@bib105],[@bib108]\]. The optimal point in time for performing HSCT would be the stage of hypocellular MDS or immunodeficiency prior development of MDS/leukemia evolution or severe organ dysfunction.

SAMD9 and SAMD9L syndromes {#sec3}
==========================

Sterile alpha motif domain-containing protein 9 ([SAMD9]{.ul}) and the paralogue gene SAMD9-like ([SAMD9L]{.ul}) are located side-by-side on chromosome 7q21. Initial study describing acquired microdeletions of 7q21 in patients with MN drew preliminary attention to these poorly characterized genes. SAMD9/9L are IFN and TNF-α responsive proteins that were shown to play a role in antiviral response \[[@bib109], [@bib110], [@bib111], [@bib112]\], tumor suppression \[[@bib113],[@bib114]\], inflammation \[[@bib115],[@bib116]\], development \[[@bib117], [@bib118], [@bib119]\] and endosomal fusion \[[@bib118],[@bib120]\]. Samd9l-deficient mice develop myeloid disease resembling human MDS with −7 \[[@bib120]\]. The first link to human disease was a description of biallelic LOF [SAMD9]{.ul} mutations (p.K1495E and p.R344X) in several consanguineous Jewish-Yemenite families with normophosphatemic familial tumor calcinosis (NFTC), however no further NFTC cases with [SAMD9]{.ul} mutations were found \[[@bib115],[@bib116]\]. In 2016, heterozygous missense [SAMD9]{.ul} mutations with GOF effect were linked to a severe early-onset condition with Myelodysplasia, Infections, Restriction of growth, Adrenal hypoplasia, Genital phenotypes and Enteropathy (MIRAGE) \[[@bib118],[@bib119]\]. At the same time, missense GOF mutations in [SAMD9L]{.ul} were described as a cause of a syndrome with progressive neurological phenotype, pancytopenia and hypocellular bone marrow (Ataxia Pancytopenia (ATXPC)) \[[@bib117],[@bib121]\]. Both conditions have a unifying phenotype of early onset myelodysplasia with monosomy 7. Following the first discoveries in syndromic cohorts, a number of studies reported germline missense [SAMD9]{.ul} and [SAMD9L]{.ul} mutations in pediatric cohorts with MDS (often without syndromic manifestation) \[[@bib122], [@bib123], [@bib124], [@bib125]\]. Recently, germline frameshift [SAMD9L]{.ul} mutations were also discovered in several children presenting with autoinflammatory panniculitis resembling Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperatures (CANDLE) syndrome \[[@bib126]\].

Penetrance and prevalence {#sec3.1}
-------------------------

SAMD9/9L syndromes are autosomal dominant syndromes resulting from GOF, mostly missense mutations with variable penetrance. [SAMD9]{.ul} mutations are associated with a high rate of *de novo* cases with very high penetrance especially in pedigrees presenting with MIRAGE syndrome. For [SAMD9L]{.ul} mutations, the penetrance for haematological disease is incomplete and has been estimated at 70% \[[@bib127]\]. Similarly, low penetrance for neurological phenotypes (that might increase with age) has been observed \[[@bib117]\].

Germline [SAMD9/9L]{.ul} mutations account for a large proportion of primary childhood MDS and the prevalence was shown to range from 8% (43/548) in a large multi-institutional consecutive cohort of the European Working Group of Childhood MDS (EWOG-MDS) \[[@bib37]\] to 17% (8/46) in a single institution report \[[@bib122]\]. Interestingly, in a French cohort of patients with idiopathic cytopenia of unknown cause ("ICUC"), 18.6% (16/86) of patients carried germline [SAMD9/9L]{.ul} mutations \[[@bib125]\].

Clinical presentation {#sec3.2}
---------------------

Multiple organ systems can be affected in [SAMD9/9L]{.ul} syndromes, with predominant haematologic, immunologic, endocrine, genital and neurologic involvement ([Fig. 1](#fig1){ref-type="fig"}). Initial clinical presentation is heterogeneous and can range from severe disease with high infant mortality, to transient cytopenia and immune dysfunction. Patients with MIRAGE ([SAMD9]{.ul}) phenotype present with early onset adrenal hypoplasia and primary adrenal insufficiency, intrauterine growth restriction, genital phenotypes (46XY females, bifid shawl scrotum, testicular dysgenesis, intra-abdominal or inguinal testes, clitoromegaly), gastrointestinal issues (enteropathy, reflux, achalasia), severe systemic infections, as well as thrombocytopenia and anemia at birth - which in some patients can be self-limiting during infancy \[[@bib37],[@bib118],[@bib119],[@bib128], [@bib129], [@bib130], [@bib131], [@bib132], [@bib133], [@bib134], [@bib135], [@bib136], [@bib137], [@bib138], [@bib139]\]. Patients with [SAMD9L]{.ul} mutations might show disease-specific neurological findings with very variable age of onset and dynamics of progression. Severe cerebellar ataxia is observed in some but not all cases \[[@bib117]\]. Some patients might show cerebellar atrophy, dysmetria, nystagmus, white matter abnormalities, and loss of Purkinje cells \[[@bib117],[@bib140],[@bib141]\].

Of note, haematological phenotype is the "common denominator" of both syndromes manifesting in the majority of patients \[[@bib117],[@bib121], [@bib122], [@bib123],[@bib125],[@bib142]\]. The haematological spectrum involves single lineage cytopenia (mostly thrombocytopenia) or pancytopenia with hypocellular marrow, and MDS with monosomy 7 or del(7q). In a large pediatric MDS cohort the majority (90%) of [SAMD9/9L]{.ul}-mutated patients presented with refractory cytopenia of childhood (RCC), while MDS with excess blasts was found in 10% of cases \[[@bib37]\]. In a small subset of patients advanced leukemic disease (AML, CMML) can be diagnosed \[[@bib37],[@bib122], [@bib123], [@bib124]\]. The median age at diagnosis in pediatric MDS with [SAMD9/9L]{.ul} was shown to be 9.6 years (0.2--17.6) which is comparable with [GATA2]{.ul}-related MDS \[[@bib37]\]. The most widespread aberrant karyotype is −7/del(7q) and shows a unique non-random pattern where the chromosome 7 with mutant [SAMD9/9L]{.ul} copy is always lost, which by itself can be considered a pathognomonic sign of SAMD9/9L syndromes ([Fig. 2](#fig2){ref-type="fig"}).

Immune dysfunction is not well defined and shows varying phenotype and severity. Mostly in patients with MIRAGE phenotype ([SAMD9]{.ul}) but also in several [SAMD9L]{.ul}-mutated patients, severe invasive infections have been described. The causative organisms were bacteria (pseudomonas aeruginosa, clostridium difficile, staphylococcus, serratia marcescens, enterococcus faecium, escherichia coli, klebsiella pneumoniae, stenotrophomonas maltophilia, streptococcus pyogenes), viruses (MRSA, CMV, EBV, rhinovirus, coronavirus, varicella), and fungi (aspergillus, candida) causing sepsis, meningitis, otitis, sinusitis, laryngitis, hepatitis, bronchiolitis, pneumonia, neonatal necrotizing enterocolitis, pancolitis, gastroenteritis, enteropathy, urinary tract infections, otitis media, ecthyma gangrenosum, warts, dental abscesses, and urethritis \[[@bib118],[@bib119],[@bib121],[@bib124],[@bib125],[@bib128], [@bib129], [@bib130], [@bib131], [@bib132], [@bib133],[@bib136], [@bib137], [@bib138], [@bib139],[@bib141],[@bib143], [@bib144], [@bib145]\]. However, the majority of non-syndromic [SAMD9/9L]{.ul}-MDS patients generally do not appear to have increased risk to develop immune dysfunction and severe infections. Decreased peripheral B/NK-cells, low IgG and IgM or increased TNF-alpha and IL-6 levels were documented in cases with [SAMD9/9L]{.ul} mutations \[[@bib121],[@bib125],[@bib128],[@bib131],[@bib135],[@bib143]\]. Other rare dysmorphic features documented in single patients include skeletal abnormalities (scoliosis, joint contracture at wrist and ankles), hearing loss, dysmorphic facial features, camptodactyly, arachnodactyly, glomerular proteinuria, dysautonomia and speech delay \[[@bib129],[@bib131]\].

SAMD9/9L genetics {#sec3.3}
-----------------

Thus far 38 distinct [SAMD9]{.ul} and 26 [SAMD9L]{.ul} mutations have been identified in 110 symptomatic patients as mutually exclusive events \[[@bib118],[@bib119],[@bib121],[@bib122],[@bib124],[@bib126],[@bib129], [@bib130], [@bib131], [@bib132], [@bib133], [@bib134],[@bib140], [@bib141], [@bib142], [@bib143],[@bib145],[@bib146]\]. The majority of these patients exhibit haematological phenotype with cytopenias, and/or MDS with monosomy 7. Most germline mutations are missense and occur predominantly in the second half (C-terminus) of SAMD9/9L proteins, encompassing the predicted P-LOOP_NTPase domain. Six cases with truncating germline mutations in [SAMD9L]{.ul} were also reported in children with CANDLE phenotype \[[@bib126]\].

Thus far, all functionally evaluated germline missense [SAMD9/9L]{.ul} mutations were shown to inhibit cell growth in 293 cellular overexpression assay \[[@bib118],[@bib119],[@bib127]\]. Of note, most mutated amino acids show moderate or weak conservation across species, thus posing a risk of being scored as 'likely benign' based on *in silico* predictors. The current state-of-art for assessment of pathogenicity includes functional validation on a research basis. However, such testing must be interpreted with caution since sensitivity and specificity have not been defined and various groups utilize different readouts \[[@bib118],[@bib119],[@bib122],[@bib127]\].

Clonal evolution and somatic reversion {#sec3.4}
--------------------------------------

The unique aspect of [SAMD9/9L]{.ul} disease mechanism is 'adaptation by aneuploidy' that is achieved by the non-random loss chromosome 7 (−7/del(7q)) which contains mutated [SAMD9/9L]{.ul} gene copy ([Fig. 2](#fig2){ref-type="fig"}) \[[@bib118],[@bib119],[@bib121],[@bib122],[@bib124],[@bib125],[@bib127],[@bib129],[@bib134],[@bib135],[@bib141], [@bib142], [@bib143], [@bib144], [@bib145]\]. The decrease of mutant allele in haematopoiesis poses a diagnostic challenge, since germline [SAMD9/9L]{.ul} mutations show decreased variant allele frequency (VAF), with VAF even below 5% (own observations), necessitating germline validation in non-haematopoietic specimens, i.e. fibroblasts.

Several case reports documented complete disappearance of −7 clones, thus far seen exclusively in young children, a phenomenon previously referred to as transient monosomy 7 syndrome \[[@bib121],[@bib122],[@bib124],[@bib127],[@bib141], [@bib142], [@bib143]\]. However, −7 is a high risk lesion with malignant propensity (i.e. due to loss of several tumor suppressor genes such as [EZH2]{.ul}). Clonal evolution to advanced MDS/AML is a recurrent complication in SAMD9/9L-related MDS with −7 and was shown to be accompanied by somatic driver mutations in [SETBP1]{.ul}, [ASXL1]{.ul}, [RUNX1]{.ul}, [PTPN11]{.ul}, [KRAS]{.ul}, [CBL]{.ul}, [EZH2]{.ul}, [ETV6]{.ul}, [BRAF]{.ul}, and [RAD21]{.ul} \[[@bib122], [@bib123], [@bib124],[@bib142]\].

Somatic revertant mosaicism with expansion of benign, corrected haematopoiesis represents another unique feature of SAMD9/9L syndromes ([Fig. 2](#fig2){ref-type="fig"}). The two mechanisms observed so far are the acquisition of truncating [SAMD9/9L]{.ul} mutations or an independent uniparental disomy of 7q (UPD7q). Somatic [SAMD9/9L]{.ul} mutations are acquired *in cis* and are thought to exert a LOF effect and "neutralize" the GOF germline mutation, as documented in cellular growth assays \[[@bib119],[@bib121],[@bib123],[@bib124],[@bib131],[@bib134],[@bib142]\]. Missense somatic [SAMD9/9L]{.ul} are rarely encountered but were also shown to modify germline mutant function \[[@bib121]\]. A true genetic reversion with replacement of the mutant [SAMD9/9L]{.ul} allele via UPD7q has been thus far reported in 11 patients who experienced spontaneous remission \[[@bib121],[@bib122],[@bib124],[@bib125],[@bib127],[@bib141], [@bib142], [@bib143]\]. This reversion likely arises through non-allelic homologous recombination in a del(7q) clone, where the wild type 7q arm is duplicated. Strikingly, the reversion seems to be definitive, as shown in patients who normalized their blood counts and marrow cellularity with normal findings up to 20 years after diagnosis \[[@bib123],[@bib125]\]. UPD7q can be considered a protective mechanism against the development of MDS, but it is not clear how it arises and how it outcompetes 7/del(7q) clones.

Therapeutic considerations {#sec3.5}
--------------------------

[SAMD9/9L]{.ul} are newly described MDS predisposition syndromes where clinical outcome data is derived from retrospective studies and no guidelines exist on prospective management. The current practice for patients mild haematological phenotypes is guided by the morphological subtype (as recommended by the EWOG-MDS working group). For example, patients with RCC without severe neutropenia and no transfusion dependency can be followed with a watch & wait strategy with periodic assessment of blood counts and yearly marrow evaluation aiming at detection of high-risk somatic changes (−7, somatic driver mutations). A very careful consideration must be given to patients with SAMD9/9L syndromes and −7, where not enough data exists to deviate from the general recommendation for pediatric MDS with −7 where HSCT is performed in a timely manner \[[@bib102]\]. Children with severe multi-organ involvement in context of MIRAGE syndrome who received HSCT were shown to have rather poor outcome complicated by syndrome-related comorbidities \[[@bib128],[@bib145]\]. On the other hand, children with [SAMD9/9L]{.ul} germline mutations who were transplanted for MDS had satisfactory outcomes with a 5 year OS of 85% \[[@bib37]\]. Going forward one might speculate that young children with clinically stable disease (MDS and −7 without severe cytopenias and without somatic leukemia mutations) might benefit from careful watching with repeated molecular studies to document loss of monosomy 7 clone and emergence of revertant UPD7q clones. At the same time however, the patients might be exposed to the risk of clonal evolution to a more advanced disease where HSCT outcome is inferior compared to initial disease state.

Practice points {#sec4}
===============

•Recently described autosomal dominant syndromes predisposing to myeloid neoplasms often manifest without pre-existing features or family history and show variable expressivity and incomplete penetrance•GATA2 and SAMD9/SAMD9L syndromes are most common germline drivers of pediatric MDS and account for at least half of pediatric MDS with monosomy 7•HSCT is indicated in patients with transfusion dependency, neutropenia, immunodeficiency, morphologically advanced disease, and high-risk cytogenetic and genetic lesions•GATA2 deficiency is a highly penetrant disease with progressive course necessitating HSCT, while SAMD9/SAMD9L syndromes can show diverse outcomes ranging from spontaneous remission (in young children) to clonal progression.

Research agenda {#sec5}
===============

•Prospective monitoring of patients with hereditary predisposition to MN might reveal risk factors for clonal evolution•It remains to be answered if a careful watch and wait strategy in stable patients with SAMD9/9L-related MDS and monosomy 7 might identify patients with spontaneous genetic reversion and disappearance of monosomy 7, and eventually become a standard approach.•Collaborative studies are required to address the question of incomplete penetrance in syndromes predisposing to MN.
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[^1]: Abbreviations: DC, dyskeratosis congenita; CMMRD, Constitutional Mismatch Repair Deficiency; NBS, Nijmegen Breakage Syndrome; AT, Ataxia telangiectasia; MN, myeloid neoplasms.

[^2]: +, present; (+), possibly present; ++, commonly present; -, absent.

[^3]: \*Approximate age range (median) assessed from literature reports; CLL chronic lymphocytic leukemia; UPD, uniparental disomy; LOH, loss of heterozygosity.
